metoclopramide has been researched along with Hypothyroidism in 18 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Hypothyroidism: A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH) before and after l-thyroxine replacement therapy." | 7.67 | Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism. ( Annunziato, L; Iodice, M; Lombardi, G; Merola, B; Miletto, P; Panza, N, 1986) |
| "Serum TSH and PRL concentrations were measured after the randomized oral administration of either metoclopramide, L-dopa, or placebo on 3 consecutive days to five patients with overt primary hypothyroidism (low serum total T4 and raised serum TSH) and to five patients with subclinical hypothyroidism (normal serum total T4 and raised serum TSH)." | 5.05 | Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: evidence for an additional feedback mechanism in the control of thyroid hormone secretion. ( Brown, NS; Feek, CM; Irvine, WJ; Sawers, JS; Seth, J; Toft, AD, 1980) |
| " Metoclopramide is DA2 receptor blockade which can accelerate to elevate the concentration of serum TSH in hypothyroidism, which is accompanied by a progressive loss of dopaminergic tone as demonstrated by a progressive increase in prolaction serum levels, especially in patients with differentiated thyroid carcinoma(DTC)." | 4.82 | [The relationship between metoclopramide and hypothalamus-pituitary-thyroid axis and it's clinical application]. ( Dai, Q; Kuang, A, 2004) |
| "To investigate the hypothesis of an altered dopaminergic activity in hypothyroidism, seven patients without thyroid tissue were studied by means of three consecutive tests: an iv bolus of TRH (200 micrograms); a continuous iv infusion (5 mg during 30 min) of metoclopramide (MCP); and a second, post-MCP, iv bolus of TRH (200 micrograms)." | 3.67 | Prolactin as a marker of dopaminergic activity at different levels of thyroid function in man. ( Cacicedo, L; Sanchez Franco, F; Santirso, RA; Varela, C; Zurita, P, 1984) |
| "The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH) before and after l-thyroxine replacement therapy." | 3.67 | Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism. ( Annunziato, L; Iodice, M; Lombardi, G; Merola, B; Miletto, P; Panza, N, 1986) |
| " The pharyngeal hypophysis from a patient with primary hypothyroidism was hypertrophic, with TSH cell hyperplasia; while that from a patient treated with metoclopramide, a dopamine-receptor-blocking drug, showed PRL cell hyperplasia." | 3.67 | Immunocytochemical evidence for the ability of the human pharyngeal hypophysis to respond to change in endocrine feedback. ( Ciocca, DR; Puy, LA; Stati, AO, 1985) |
| "In order to clarify if hyper- and hypothyroidism change by feed-back mechanisms the dopaminergic controlled release of PRL, TSH and GH, the serum values of these hormones were measured before and following iv administration of 5 mg metoclopramide in 10 hyperthyroid, 11 euthyroid and 10 primary hypothyroid age-matched females, all consecutively investigated." | 3.67 | The influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone. ( Eskildsen, PC; Kirkegaard, CB, 1985) |
| " This diabetes insipidus is reversible, non-progressive, unrelated to plasma level, and distinct in attack from lithium-induced hypothyroidism, which may occur at low dosage but is also usually of late onset and reversible or treatable with thyroxine while lithium is continued." | 3.65 | Blood levels and management of lithium treatment. ( Crammer, JL; Crane, G; Rosser, RM, 1974) |
| "Women with spontaneous primary hypothyroidism had a longer duration of illness (72 +/- 12 vs." | 1.26 | Hyperprolactinemia and galactorrhea: spontaneous versus iatrogenic hypothyroidism. ( Campino, C; Contreras, P; Generini, G; Michelsen, H; Pumarino, H, 1981) |
| "response in hypothyroidism is significantly correlated with both T3 and T4 levels, suggesting suppression of this inhibitory pathway in increasingly severe hypothyroidism." | 1.26 | Evidence for dopaminergic control of thyrotrophin secretion in man. ( Hall, R; Heath, M; Mora, B; Scanlon, MF; Shale, DJ; Snow, MH; Weightman, DR, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (77.78) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Q | 1 |
| Kuang, A | 1 |
| Frey, HM | 1 |
| Haug, E | 1 |
| Holdaway, IM | 1 |
| Evans, MC | 1 |
| Sheehan, A | 1 |
| Ibbertson, HK | 1 |
| Jarzab, B | 1 |
| Skrzypek, J | 1 |
| Waler, J | 1 |
| Bałdys, A | 1 |
| Babińska, A | 1 |
| Varela, C | 1 |
| Cacicedo, L | 1 |
| Santirso, RA | 1 |
| Zurita, P | 1 |
| Sanchez Franco, F | 1 |
| Contreras, P | 1 |
| Generini, G | 1 |
| Michelsen, H | 1 |
| Pumarino, H | 1 |
| Campino, C | 1 |
| Scanlon, MF | 2 |
| Chan, V | 1 |
| Heath, M | 2 |
| Pourmand, M | 1 |
| Rodriguez-Arnao, MD | 1 |
| Weightman, DR | 2 |
| Lewis, M | 1 |
| Hall, R | 2 |
| Feek, CM | 1 |
| Sawers, JS | 1 |
| Brown, NS | 1 |
| Seth, J | 1 |
| Irvine, WJ | 1 |
| Toft, AD | 1 |
| Loviselli, A | 1 |
| Martellotta, MC | 1 |
| Velluzzi, F | 1 |
| Cambosu, MA | 1 |
| Mossa, P | 1 |
| Caradonna, A | 1 |
| Palermo, M | 1 |
| Fratta, W | 1 |
| Martino, E | 1 |
| Mora, B | 1 |
| Shale, DJ | 1 |
| Snow, MH | 1 |
| Delitala, G | 1 |
| Cowden, EA | 1 |
| Ratcliffe, WA | 1 |
| Beastall, GH | 1 |
| Ratcliffe, JG | 1 |
| Gerasimov, G | 1 |
| Chernova, T | 1 |
| Goncharov, N | 1 |
| Gerhard, I | 1 |
| Eggert-Kruse, W | 1 |
| Merzoug, K | 1 |
| Klinga, K | 1 |
| Runnebaum, B | 1 |
| Lombardi, G | 1 |
| Iodice, M | 1 |
| Miletto, P | 1 |
| Merola, B | 1 |
| Panza, N | 1 |
| Annunziato, L | 1 |
| Ciocca, DR | 1 |
| Puy, LA | 1 |
| Stati, AO | 1 |
| Eskildsen, PC | 1 |
| Kirkegaard, CB | 1 |
| Crammer, JL | 1 |
| Rosser, RM | 1 |
| Crane, G | 1 |
1 review available for metoclopramide and Hypothyroidism
| Article | Year |
|---|---|
[The relationship between metoclopramide and hypothalamus-pituitary-thyroid axis and it's clinical application].
Topics: Dopamine Antagonists; Humans; Hyperthyroidism; Hypothalamo-Hypophyseal System; Hypothyroidism; Metoc | 2004 |
1 trial available for metoclopramide and Hypothyroidism
| Article | Year |
|---|---|
Influence of thyroid status on dopaminergic inhibition of thyrotropin and prolactin secretion: evidence for an additional feedback mechanism in the control of thyroid hormone secretion.
Topics: Feedback; Female; Humans; Hypothalamo-Hypophyseal System; Hypothyroidism; Kinetics; Levodopa; Metocl | 1980 |
16 other studies available for metoclopramide and Hypothyroidism
| Article | Year |
|---|---|
Influence of dopaminergic inhibition on serum levels of thyrotrophin and prolactin in patients with hypothyroidism before and after prolonged oral administration of TRH.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Hypothyroidism; Male; Metoclopramide; Middle Aged | 1983 |
Low thyroxine levels in some hyperprolactinemic patients due to dopaminergic suppression of thyrotropin.
Topics: Adult; Domperidone; Dopamine; Female; Humans; Hypothalamus; Hypothyroidism; Male; Metoclopramide; Mi | 1984 |
The effect of metoclopramide on serum thyrotropin level in various stages of hypothyroidism.
Topics: Adolescent; Adult; Female; Humans; Hypothyroidism; Male; Metoclopramide; Middle Aged; Stimulation, C | 1984 |
Prolactin as a marker of dopaminergic activity at different levels of thyroid function in man.
Topics: Adult; Aged; Dopamine; Female; Humans; Hypothyroidism; Male; Metoclopramide; Middle Aged; Prolactin; | 1984 |
Hyperprolactinemia and galactorrhea: spontaneous versus iatrogenic hypothyroidism.
Topics: Adolescent; Adult; Aged; Female; Galactorrhea; Humans; Hypothyroidism; Iatrogenic Disease; Lactation | 1981 |
Dopaminergic control of thyrotropin, alpha-subunit, thyrotropin beta-subunit, and prolactin in euthyroidism and hypothyroidism: dissociated responses to dopamine receptor blockade with metoclopramide in hypothyroid subjects.
Topics: Adult; Aged; Aging; Dopamine; Female; Humans; Hypothyroidism; Kinetics; Male; Metoclopramide; Middle | 1981 |
An altered thyroid status does not alter the met-enkephalin plasma concentration in humans.
Topics: Adult; Enkephalin, Methionine; Female; Goiter; Humans; Hyperthyroidism; Hypothyroidism; Male; Metocl | 1995 |
Evidence for dopaminergic control of thyrotrophin secretion in man.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Hypothyroidism; Male; Metoclopramide; Middle Aged | 1977 |
Dopamine and T.S.H. secretion in man.
Topics: Depression, Chemical; Dopamine; Drug Antagonism; Humans; Hypothyroidism; Infusions, Parenteral; Meto | 1977 |
Laboratory assessment of prolactin status.
Topics: Adolescent; Adult; Age Factors; Circadian Rhythm; Female; Humans; Hypophysectomy; Hypothalamo-Hypoph | 1979 |
Monoamine regulation of prolactin and TSH secretion in hypothyroidism.
Topics: Adenoma; Adult; Cyproheptadine; Dopamine; Female; Humans; Hyperprolactinemia; Hypothyroidism; Metocl | 1992 |
Thyrotropin-releasing hormone (TRH) and metoclopramide testing in infertile women.
Topics: Dehydroepiandrosterone; Dopamine Agents; Estradiol; Female; Fertilization; Follicle Stimulating Horm | 1991 |
Prolactin and TSH response to TRH and metoclopramide before and after l-thyroxine therapy in subclinical hypothyroidism.
Topics: Adult; Female; Humans; Hypothyroidism; Male; Metoclopramide; Middle Aged; Prolactin; Thyrotropin; Th | 1986 |
Immunocytochemical evidence for the ability of the human pharyngeal hypophysis to respond to change in endocrine feedback.
Topics: Adenoma; Adolescent; Aged; Bronchial Diseases; Endocrine Glands; Feedback; Female; Histocytochemistr | 1985 |
The influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone.
Topics: Adult; Aged; Dopamine; Feedback; Female; Growth Hormone; Humans; Hyperthyroidism; Hypothyroidism; Me | 1985 |
Blood levels and management of lithium treatment.
Topics: Administration, Oral; Adult; Aged; Carbimazole; Delayed-Action Preparations; Dementia; Depression; D | 1974 |